Antares Pharma Competitors

Antares Pharma (NASDAQ:ATRS) and Align Technology (NASDAQ:ALGN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, valuation, analyst recommendations and earnings.

Analyst Ratings

This is a breakdown of current recommendations for Antares Pharma and Align Technology, as provided by MarketBeat.com.

Antares Pharma currently has a consensus target price of $5.6250, indicating a potential upside of 38.21%. Align Technology has a consensus target price of $501.3333, indicating a potential downside of 16.65%. Given Antares Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Antares Pharma is more favorable than Align Technology.

Valuation & Earnings

This table compares Antares Pharma and Align Technology's top-line revenue, earnings per share and valuation.

Align Technology has higher revenue and earnings than Antares Pharma. Antares Pharma is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Antares Pharma and Align Technology's net margins, return on equity and return on assets.

Institutional and Insider Ownership

39.9% of Antares Pharma shares are held by institutional investors. Comparatively, 85.8% of Align Technology shares are held by institutional investors. 5.9% of Antares Pharma shares are held by company insiders. Comparatively, 1.2% of Align Technology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Antares Pharma has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500. Comparatively, Align Technology has a beta of 1.68, suggesting that its share price is 68% more volatile than the S&P 500.

Summary

Align Technology beats Antares Pharma on 10 of the 14 factors compared between the two stocks.

West Pharmaceutical Services (NYSE:WST) and Antares Pharma (NASDAQ:ATRS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and valuation.

Analyst Recommendations

This is a breakdown of current ratings for West Pharmaceutical Services and Antares Pharma, as provided by MarketBeat.

West Pharmaceutical Services presently has a consensus target price of $310.00, indicating a potential upside of 4.48%. Antares Pharma has a consensus target price of $5.6250, indicating a potential upside of 38.21%. Given Antares Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Antares Pharma is more favorable than West Pharmaceutical Services.

Earnings and Valuation

This table compares West Pharmaceutical Services and Antares Pharma's top-line revenue, earnings per share and valuation.

West Pharmaceutical Services has higher revenue and earnings than Antares Pharma. Antares Pharma is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares West Pharmaceutical Services and Antares Pharma's net margins, return on equity and return on assets.

Institutional & Insider Ownership

92.6% of West Pharmaceutical Services shares are held by institutional investors. Comparatively, 39.9% of Antares Pharma shares are held by institutional investors. 1.6% of West Pharmaceutical Services shares are held by company insiders. Comparatively, 5.9% of Antares Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk and Volatility

West Pharmaceutical Services has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, Antares Pharma has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500.

Summary

West Pharmaceutical Services beats Antares Pharma on 9 of the 14 factors compared between the two stocks.

The Cooper Companies (NYSE:COO) and Antares Pharma (NASDAQ:ATRS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and valuation.

Analyst Recommendations

This is a breakdown of current ratings for The Cooper Companies and Antares Pharma, as provided by MarketBeat.

The Cooper Companies presently has a consensus target price of $384.25, indicating a potential downside of 0.95%. Antares Pharma has a consensus target price of $5.6250, indicating a potential upside of 38.21%. Given Antares Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Antares Pharma is more favorable than The Cooper Companies.

Earnings and Valuation

This table compares The Cooper Companies and Antares Pharma's top-line revenue, earnings per share and valuation.

The Cooper Companies has higher revenue and earnings than Antares Pharma. Antares Pharma is trading at a lower price-to-earnings ratio than The Cooper Companies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares The Cooper Companies and Antares Pharma's net margins, return on equity and return on assets.

Institutional & Insider Ownership

95.8% of The Cooper Companies shares are held by institutional investors. Comparatively, 39.9% of Antares Pharma shares are held by institutional investors. 1.4% of The Cooper Companies shares are held by company insiders. Comparatively, 5.9% of Antares Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk and Volatility

The Cooper Companies has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, Antares Pharma has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500.

Summary

The Cooper Companies beats Antares Pharma on 9 of the 14 factors compared between the two stocks.

DENTSPLY SIRONA (NASDAQ:XRAY) and Antares Pharma (NASDAQ:ATRS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and valuation.

Analyst Recommendations

This is a breakdown of current ratings for DENTSPLY SIRONA and Antares Pharma, as provided by MarketBeat.

DENTSPLY SIRONA presently has a consensus target price of $55.3333, indicating a potential downside of 13.76%. Antares Pharma has a consensus target price of $5.6250, indicating a potential upside of 38.21%. Given Antares Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Antares Pharma is more favorable than DENTSPLY SIRONA.

Earnings and Valuation

This table compares DENTSPLY SIRONA and Antares Pharma's top-line revenue, earnings per share and valuation.

DENTSPLY SIRONA has higher revenue and earnings than Antares Pharma. Antares Pharma is trading at a lower price-to-earnings ratio than DENTSPLY SIRONA, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares DENTSPLY SIRONA and Antares Pharma's net margins, return on equity and return on assets.

Institutional & Insider Ownership

96.0% of DENTSPLY SIRONA shares are held by institutional investors. Comparatively, 39.9% of Antares Pharma shares are held by institutional investors. 0.5% of DENTSPLY SIRONA shares are held by company insiders. Comparatively, 5.9% of Antares Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk and Volatility

DENTSPLY SIRONA has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, Antares Pharma has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500.

Summary

Antares Pharma beats DENTSPLY SIRONA on 9 of the 14 factors compared between the two stocks.

Haemonetics (NYSE:HAE) and Antares Pharma (NASDAQ:ATRS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and valuation.

Analyst Recommendations

This is a breakdown of current ratings for Haemonetics and Antares Pharma, as provided by MarketBeat.

Haemonetics presently has a consensus target price of $144.80, indicating a potential upside of 24.21%. Antares Pharma has a consensus target price of $5.6250, indicating a potential upside of 38.21%. Given Antares Pharma's higher possible upside, analysts plainly believe Antares Pharma is more favorable than Haemonetics.

Earnings and Valuation

This table compares Haemonetics and Antares Pharma's top-line revenue, earnings per share and valuation.

Haemonetics has higher revenue and earnings than Antares Pharma. Antares Pharma is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Haemonetics and Antares Pharma's net margins, return on equity and return on assets.

Institutional & Insider Ownership

96.2% of Haemonetics shares are held by institutional investors. Comparatively, 39.9% of Antares Pharma shares are held by institutional investors. 1.6% of Haemonetics shares are held by company insiders. Comparatively, 5.9% of Antares Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk and Volatility

Haemonetics has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, Antares Pharma has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500.

Summary

Haemonetics beats Antares Pharma on 8 of the 12 factors compared between the two stocks.

Quidel (NASDAQ:QDEL) and Antares Pharma (NASDAQ:ATRS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and valuation.

Analyst Recommendations

This is a breakdown of current ratings for Quidel and Antares Pharma, as provided by MarketBeat.

Quidel presently has a consensus target price of $262.75, indicating a potential upside of 106.24%. Antares Pharma has a consensus target price of $5.6250, indicating a potential upside of 38.21%. Given Quidel's higher possible upside, equities research analysts plainly believe Quidel is more favorable than Antares Pharma.

Profitability

This table compares Quidel and Antares Pharma's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Quidel and Antares Pharma's top-line revenue, earnings per share and valuation.

Quidel has higher revenue and earnings than Antares Pharma. Antares Pharma is trading at a lower price-to-earnings ratio than Quidel, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

84.0% of Quidel shares are held by institutional investors. Comparatively, 39.9% of Antares Pharma shares are held by institutional investors. 14.1% of Quidel shares are held by company insiders. Comparatively, 5.9% of Antares Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk and Volatility

Quidel has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500. Comparatively, Antares Pharma has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500.

Summary

Quidel beats Antares Pharma on 10 of the 14 factors compared between the two stocks.